Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Drug Alcohol Depend. 2020 Jul 15;214:108179. doi: 10.1016/j.drugalcdep.2020.108179

Fig. 4.

Fig. 4.

AB-FUBINACA has short-acting, in vivo cannabinoid effects. Male and female mice were injected with AB-FUBINACA (3 mg/kg, i.p.) or THC (50 mg/kg) and tested repeatedly in a modified tetrad battery, following baseline testing. The effects of AB-FUBINACA abated more quickly than the effects of THC in catalepsy (A), antinociception (B), and hypothermia (C). n = 8[4 m/4f]/group);*p<.05 vs. baseline. A second group of mice was injected with vehicle (i.e., 0 h), 0.25, 0.5, 1, 4, or 12 h prior to tissue collection (D). AB-FUBINACA levels in whole brain homogenates were quantified by UHPLC-MS/MS (n = 6 [3 m/3f]/group); *p<.05 vs. vehicle group. Data represent mean±SEM.